Pigeon Forge students raise 20 grand to help fight cancer

PIGEON FORGE, Tenn.(WVLT)– A big surprise Tuesday evening at a Relay for Life rally in Sevier County.

The American Cancer Society hit up Pigeon Forge High School, looking for new recruits, teams, and team members.

Imagine their surprise when they also got a check. A check for $20,000!

Students at Pigeon Forge High raised the money by selling t-shirts and shoelaces.

Crystal Mantooth with the American Cancer Society said its all about helping people. “We want to help people get well we want to help them stay well we want to help find cures and we want to help them fight back. So we use that money for programs and services here locally and to help fund research that's needed to find a cure.”

Last year, Sevier County Relay for Life raised more than $400,000
.

Continued here:
Pigeon Forge students raise 20 grand to help fight cancer

Posted in Cancer Cures | Tagged , , , , , , , , , , | Comments Off

Shoestring Living: Learn to barter

Candidates target Santorum ahead of Michigan primary

Republican presidential candidate Mitt Romney believes he will win in his home state of Michigan despite trailing in the polls to rival Rick Santorum. Jan Crawford reports.

2/21/2012

Candidates target Santorum ahead of Michigan primary

WH admits no quick fix to rising gas prices

The White House is worried rising gas prices could cripple the economic recovery and hurt President Obama's hopes for re-election. Norah O'Donnell reports Republican presidential candidate Newt Gingrich took the opportunity to add lowering oil prices to his campaign promises.

2/21/2012

WH admits no quick fix to rising gas prices

Ex-LA Teacher Pleads Not Guilty to Lewd Acts

A former Los Angeles teacher has pleaded not guilty to committing lewd acts with 23 children in his classroom and his lawyer asks the media not to turn the case into a spectacle. (Feb. 21)

2/21/2012

Ex-LA Teacher Pleads Not Guilty to Lewd Acts

FDA: New Suppliers to Ease Cancer Drug Shortages

Federal regulators have approved new suppliers for two crucial cancer drugs, easing critical shortages ratcheting up fears that patients, particularly children with leukemia, would miss life-saving treatments. (Feb. 21)

2/21/2012

FDA: New Suppliers to Ease Cancer Drug Shortages

14-year-old Dies at Party After Inhaling Helium

A 14-year-old girl passes out at a party in Oregon after inhaling helium from a tank. Ashley Long later died at a hospital, and authorities think that breath of helium played a part in her death. (Feb. 21)

2/21/2012

14-year-old Dies at Party After Inhaling Helium

Quran Burning Sparks Angry Afghan Protest

Afghans protested outside of Bagram Air Base, Afghanistan, after learning that copies of the Quran were burned there. The leader of NATO forces in Afghanistan promised a full investigation. (Feb. 21)

2/21/2012

Quran Burning Sparks Angry Afghan Protest

See more here:
Shoestring Living: Learn to barter

Posted in Oncologist | Tagged , , , , , , , , , | Comments Off

Carrboro man to get stem cell transplant

Published: Feb 22, 2012 02:00 AM
Modified: Feb 20, 2012 10:41 PM


Carrboro man to get stem cell transplant
Treatment a first at UNC

BY ELIZABETH SWARINGEN, Special to The Chapel Hill News

CHAPEL HILL – Three infusions of your own stem cells – each infusion over a 21-day hospitalization – can seem daunting. But, when it's your best chance for beating a recurrence of testicular cancer, you look forward to it.”It doesn't seem intimidating to me at all,” said David Alston, 42, of Carrboro. “You don't normally think of stem cell bone marrow transplants as treatment for testicular cancer, but it has been done in New York with success. I'm pleased it's available to me here at UNC Hospitals.”This month Alston is having the first triple-tandem transplant done in an adult at UNC Hospitals.The process involves harvesting and freezing his own stem cells, receiving high-dose chemotherapy to attack the cancer, then having the stem cells infused over three back-to-back hospitalizations.”He's young and otherwise healthy, and we think this is the right thing for him,” said Dr. Paul M. Armistead, assistant professor of medicine in the Division of Hematology/Oncology, a member of the UNC Lineberger Comprehensive Cancer Center and leader of Alston's transplant team. “This is his best chance for being cured.”Alston, a Charlotte native, was diagnosed with aggressive testicular cancer in March 2011 after experiencing an “avalanche of symptoms.”"I didn't have a lump, but I had some weird back pain and loss of feeling in one leg,” David said. “By the time I had some scans, we found lymph node involvement in a lot of places. Essentially, the cancer had gone on vacation all over my body.”Testicular cancer is one of the more curable cancers, often cured in the first round of chemotherapy, said Dr. Kim Rathmell, associate professor of medicine, a member of UNC Lineberger Comprehensive Cancer Center and Alston's medical oncologist.Aggressive chemotherapy sent the cancer into remission, and by August Alston returned to his long-time job at Weaver Street Market in Chapel Hill's Southern Village.Routine blood test results in December surprised everyone: the cancer was back.”Because of the way David's cancer came back, a more aggressive approach than chemotherapy alone was needed,” said Rathmell, adding how hard it was knowing Alston faced treatment again. “I shop that store, and I had seen him back at work.”Dr. Matthew Milowsky, who participated in the development of the triple-tandem transplant for testicular cancer at Memorial Sloan Kettering in New York City, joined UNC Lineberger Comprehensive Cancer Center last fall as co-director of UNC's urologic oncology program. Rathmell quickly recruited him to Alston's team.”We have everything we need here at UNC to treat David,” Rathmell said. “Had David come to us five years ago, when this recommended treatment was newer and we didn't have local expertise, I would likely have referred him elsewhere. Today, we are very comfortable doing this transplant here. And it's a total team approach.”In January, Alston began receiving two types of chemotherapy to mobilize his stem cells in preparation for collection.This chemotherapy featured one less drug than what he endured after initial diagnosis and yielded fewer side effects.”It was night and day difference,” he said, remembering the physical and mental side effects that sent him into the ICU last spring. “By comparison, what I'm doing in preparation for the transplant has been rather effortless.”But the process is complicated and has many moving parts.”David will have five chemotherapy infusions administered by two separate medical teams that have to work together through a lot of logistics about what happens when,” said Armistead. “That David is organized and intelligent and sends a lot of questions to Dr. Rathmell and me via email, he's helping himself stay on top of things. Having a patient who is fully aware of what's going on has kept us on our toes and helped us develop and coordinate a more fool-proof system.”Still, as a single, stubbornly independent man, Alston needed help and support. Luckily, his mother, Barbara Alston, a retired medical professional from Concord, is by his side.Both are staying at SECU Family House, the 40-bedroom hospital hospitality house minutes from UNC Hospitals for seriously ill adult patients and their family member caregivers.The Alstons will stay at Family House during the nine weeks total that David is expected to be hospitalized. He will join her between transplants and for post-transplant monitoring.”It's a comfort being here at Family House,” Barbara Alston said. “If we need something, it's taken care of, both here and at the hospital. I'm assured David's getting the care he needs. I'm helping him whenever and wherever I can.”SECU Family House will play an even larger role in Alston's recovery post-transplant, both Rathmell and Armistead agreed.”This treatment is intense, and David will be more in the hospital than out,” Rathmell said. “He will need a solid support system, and he has that with his mother. It's a fragile time, and she has his best interest at heart.”"Post-transplant David will need to be monitored closely because his immune system will be very weak,” Armistead said. “His mother's medical background is a bonus. The Family House folks are used to immune-suppressed patients and can get them to the hospital quickly if needed.”Alston has kept himself swimming in information to minimize the fear and mystery. Barbara has been the great translator when his own efforts didn't yield the level of detail he needed.”The constant learning gives it all a degree of routine that took some of the scariness away,” Alston said. “But you can't be too independent or too brainy when you have cancer.”Cancer blows you out of the water, but it leaves you with valuable insight,” he said. “How you deal with cancer is self-guided and you learn things about yourself and your personality that you never knew. It's the ultimate in snatching the silver lining from a cloud.”

Elizabeth Swaringen wrote this article for UNC Health Care.

View original post here:
Carrboro man to get stem cell transplant

Posted in Stem Cell Cancer | Tagged , , , , , , , | Comments Off

Stem cell implants boost monkeys with Parkinson's

Monkeys suffering from Parkinson's disease show a marked improvement when human embryonic stem cells are implanted in their brains, in what a Japanese researcher said Wednesday was a world first.

A team of scientists transplanted the stem cells into four primates that were suffering from the debilitating disease.

The monkeys all had violent shaking in their limbs — a classic symptom of Parkinson's disease — and were unable to control their bodies, but began to show improvements in their motor control after about three months, Kyoto University associate professor Jun Takahashi told AFP.

About six months after the transplant, the creatures were able to walk around their cages, he said.

“Clear improvements were confirmed in their movement,” he said.

Parkinson's disease is a progressive neurological illness linked to a decrease in dopamine production in the brain. There is currently no medical solution to this drop off in a key neurotransmitter.

The condition, which generally affects older people, gained wider public recognition when Hollywood actor Michael J. Fox revealed he was a sufferer.

Takahashi said at the time of the implant about 35 percent of the stem cells had already grown into dopamine neuron cells, with around 10 percent still alive after a year.

He said he wants to improve the effectiveness of the treatment by increasing the survival rate of dopamine neuron cells to 70 percent.

“The challenge before applying it to a clinical study is to raise the number of dopamine neuron cells and to prevent the development of tumours,” he said.

“I would like to make this operation more effective and safe” before clinical trials, Takahashi said.

Takahashi said so far he had used embryonic stem cells, which are harvested from foetuses, but would likely switch to so-called Induced Pluripotent Stem (iPS) cells, which are created from human skin, for the clinical trial.

His team, which has also transplanted iPS cells into monkeys, are now looking to see if the primates with Parkinson's disease show similar improvements in their motor control.

Scientists say the use of human embryonic stem cells as a treatment for cancer and other diseases holds great promise, but the process has drawn fire from religious conservatives, among others.

Opponents say harvesting the cells, which have the potential to become any cell in the human body, is unethical because it involves the destruction of an embryo.

The Japanese government currently has no guidelines on the use of human stem cells in clinical research.

In October last year, the Court of Justice of the European Union banned the patenting of stem cells when their extraction causes the destruction of a human embryo, a ruling that could have repercussions on medical research.

Scientists warned that the ruling would damage stem cell research in Europe, while the Catholic church hailed it as a victory for the protection of human life.

See the article here:
Stem cell implants boost monkeys with Parkinson's

Posted in Stem Cell Cancer | Tagged , , , , , , , , , , , , , , | Comments Off

National briefs: Cancer drug supply to rise

LOS ANGELES — The Food and Drug Administration has moved to increase the supplies of two needed cancer-treatment drugs and on Tuesday issued a draft guidance on how to cope with the problem of drug shortages.

The federal agency announced that it will temporarily allow the importing of a replacement drug for Doxil, a drug used in the treatment of ovarian and other cancers that has been unavailable for new patients for months.

It also said it has approved another supplier for a preservative-free version of methotrexate, a drug used for children with one type of leukemia and for treatment of bone cancer. Preservatives can cause problems for children and for those getting high doses as part of their cancer treatment. Adequate methotrexate supplies have been a problem since about 2008.

Fannie, Freddie shrinking

WASHINGTON — The government regulator for Fannie Mae and Freddie Mac has submitted a plan to Congress that would shrink the mortgage giants' role in the housing market.

The Federal Housing Finance Agency's proposal was released Tuesday and would mean fewer mortgages are backed by the government. Under the plan, Fannie and Freddie could also increase its prices to guarantee loans and establish agreements with private investors to take on added credit risk.

Payroll tax an Obama win

WASHINGTON — The $143 billion payroll tax cut won by President Barack Obama may be the last significant measure he receives from a deeply divided Congress that promises to only get more polarized as Election Day approaches.

Mr. Obama's coveted renewal of the payroll tax cut for 160 million workers and jobless benefits for millions more caps a five-month campaign-style drive against reluctant Republicans who were eager to wipe the issue from the election-year agenda.

Scientist admits he lied

WASHINGTON — A noted California scientist and environmental activist has admitted that he assumed a false identity to obtain and distribute internal documents from a libertarian group that questions climate change.

In a statement published on The Huffington Post, Peter Gleick apologized for his actions, and said his judgment was clouded by his “frustration with the ongoing efforts — often anonymous, well-funded and coordinated — to attack climate science and scientists … and by the lack of transparency of the organizations involved.”

Salute to the blues

WASHINGTON — Mick Jagger, B.B. King, Buddy Guy and Jeff Beck were among the blues artists performing Tuesday in the eighth installment of the “In Performance at the White House” series in honor of Black History Month.

The concert comes a day before President Barack Obama is to speak at the construction site for the Smithsonian's National Museum of African American History and Culture, to open in 2015.

Also in the nation . . .

Fans who were killed and injured last Aug. 13 when stage rigging and sound equipment collapsed onto them as they awaited a Sugarland concert at the Indiana State Fair failed to take steps to ensure their own safety, the country duo's attorneys said in response to a civil suit. … One of four versions of Edvard Munch's celebrated work “The Scream” will be for sale at Sotheby's in New York on May 2, the auction house announced Tuesday.

— Compiled from news services

First published on February 22, 2012 at 12:00 am

Read more here:
National briefs: Cancer drug supply to rise

Posted in Cancer Treatment | Tagged , , , , , , , , , , , , | Comments Off

Malaria drug may help boost cancer therapy

Published: Feb. 21, 2012 at 8:56 PM

VANCOUVER, British Columbia, Feb. 21 (UPI) — Blocking autophagy — the process of “self-eating” within cells — might be a viable way to enhance cancer treatment effectiveness, U.S. researchers said.

Dr. Ravi K. Amaravadi, an assistant professor at the Perelman School of Medicine and Abramson Cancer Center at the University of Pennsylvania, and his laboratory demonstrated adding hydroxychloroquine — a Food and Drug Administration-approved drug used commonly for malaria and rheumatoid arthritis — to many cancer therapies, including chemotherapy, targeted therapy, radiation and immunotherapy.

It can enhance the anti-tumor activity of these drugs in laboratory models of treatment-resistant cancers and ongoing clinical trials, Amaravadi said.

Autophagy is increased in cancer cells — normally, it is a survival pathway allowing a cell to recycle damaged proteins when it's under stress and reuse the damaged parts to fuel further growth.

However, cancer cells might be addicted to autophagy, since this innate response may be a critical means by which the cells survive nutrient limitation and lack of oxygen commonly found within tumors. It might explain how some cancer cells evade chemotherapies, the study said.

Nearly 30 Phase I and Phase II clinical trials involving hydroxychloroquine have begun or are in the planning stages in many different malignancies, including melanoma, multiple myeloma, renal cell carcinoma, colon cancer, prostate cancer and breast cancer, Amaravadi said.

The findings were presented at the annual American Association for Advancement of Science meeting in Vancouver.

Here is the original post:
Malaria drug may help boost cancer therapy

Posted in Cancer Treatment | Tagged , , , , , , , , , , , , | Comments Off

Venezuela's Chavez faces new surgery in cancer fight

Months after declaring himself cancer-free, Venezuelan President Hugo Chavez said he will soon undergo surgery to remove a lesion in his pelvis, where a malignant tumor was extracted in 2011.

The news raised new questions about Chavez's health as the leftist leader, seeking re-election, faces a serious challenge from a unified opposition candidate in an October presidential vote.

Chavez, who has been in power since 1999, said the lesion was found during a medical checkup over the weekend in Cuba, where he first underwent cancer surgery on his pelvic area in June.

“It is a small lesion of nearly two centimeters in diameter, very clearly visible,” Chavez said on state-run VTV television, adding it was “in the same area where a tumor was removed nearly a year ago.”

“There'll have to be a new operation to extract it and have it examined to see if it's malignant or not.”

The former paratrooper said that there was “no metastasis” and denied his condition was terminal, insisting he was feeling “in good physical condition to confront this battle.”

“No one needs to get upset, and no one ought to start celebrating: because independent of what my personal fate may be, there is a driving force behind this revolution and nobody, nothing is going to stop it,” Chavez said.

His statement came after rumors about his ill health had spread on social networking sites.

Chavez said it had not yet been decided where the operation would take place, noting there were “several possibilities.” He added that the surgery would be less complicated than the one he underwent in June.

The Venezuelan leader has said he was declared cancer-free after that surgery and four rounds of chemotherapy, but details about his condition have been kept secret.

Venezuelan officials said only that the tumor was removed from his pelvic area, leading some to speculate that he was suffering from colon cancer.

Chavez is facing a strong election challenge from Henrique Capriles, who was chosen as the sole opposition candidate in a heavily attended presidential primary earlier this month.

Capriles, the 39-year-old governor of Miranda state, defeated five other candidates in the first-ever primary by the traditionally fractured opposition.

The opposition has this time joined forces in an effort to defeat Chavez, an ally of Cuba and harsh critic of the United States who has been criticized for jailing political opponents and restricting media opposition.

The incumbent had displayed signs of picking up the pace of his schedule in recent months, resuming weekly television and radio broadcasts, delivering rousing speeches and greeting supporters.

Backed by state media and willing to use Venezuela's petrodollars to subsidize food and fuel, the firebrand leader remains popular among the country's working class and has promoted a raft of new social programs as he seeks re-election.

Chavez, who once said he hoped to govern Venezuela through 2030, claims he will win a new six-year term “with 70 percent of the vote” and has said he doesn't care who he is running against.

Recent opinion polls have given Chavez a lead over Capriles, but around a third of Venezuelans say they are still undecided.

Capriles, a moderate who describes his politics as center-left, has argued that Venezuela can replicate Brazil's model of economic development, which mixes free market economic reforms and enhanced social programs.

As the race heats up for the October 7 vote, Chavez last week attacked Capriles, calling him a “pig,” a “low-life” and “the candidate of the bourgeois, of capitalism, of (US) imperialism.”

Capriles has so far brushed off the criticism.

“I don't feel like he is targeting me, nor do I feel uncomfortable,” he said in a Sunday interview with the El Universal daily.

“Insults and put-downs are the typical recourse of an exhausted, hulking boxer,” said the youthful marathon runner with movie-star looks.

Read the original post:
Venezuela's Chavez faces new surgery in cancer fight

Posted in Cancer | Tagged , , , , , , , , , , | Comments Off

Local breast cancer walk steps off

DeKALB – The American Cancer Society is looking for community members to get involved in the inaugural Making Strides Against Breast Cancer walk in DeKalb. Volunteers are needed to serve on the planning committee for this event.?

Making Strides is a noncompetitive walk supporting the society’s mission to help people stay well by preventing cancer or detecting it early; help people get well by being there for them during and after a cancer diagnosis; by finding cures through investment in groundbreaking discovery; and by fighting back by rallying lawmakers to pass laws to defeat cancer and by rallying communities worldwide to join the fight.

Since 1993, Making Strides Against Breast Cancer has seen? 8 million walkers have raised more than $400 million.

The first Strides Council meeting to help plan this new event is scheduled from 6 to 7 p.m., Wednesday, March 7, at Sweet Dream Desserts in DeKalb. The American Cancer Society is joined by Kishwaukee Health System in taking a leadership position in the community’s fight against breast cancer. For more information about the DeKalb Making Strides event or volunteering at the walk, call 630-879-9009 or email Dekalb.Strides@cancer.org.

Previous Page|1|Next Page

See original here:
Local breast cancer walk steps off

Posted in Cancer Cures | Tagged , , , , , , , | Comments Off

Molecular Response Announces Key Agreement in Translational Oncology with OncoMed Pharmaceuticals

SAN DIEGO–(BUSINESS WIRE)–

Molecular Response (MRL), a privately held molecular diagnostic services company and a leader in the identification of target populations for high value therapeutics, announced today an agreement with OncoMed Pharmaceuticals, Inc., significantly expanding the companies’ successful pilot program to develop unique patient-derived tumor xenografts (PDX), through the use of Molecular Response’s proprietary ‘living’ cell bank of primary tumor cells.

OncoMed is a privately held clinical development stage biopharmaceutical company developing therapeutics that target the biologic pathways critical to tumor initiating cells, also known as “cancer stem cells.” Under the terms of the agreement, the collaboration will deliver molecularly characterized PDX models for multiple cancer indications, with full utilization of Molecular Response’s highly optimized pre-screening and characterization methodologies. This will allow OncoMed to expand their already extensive bank of proprietary xenograft models derived from freshly resected human cancers based on the molecular profile of the tumors as well as complement OncoMed’s existing biomarker and patient selection efforts. Financial terms of the collaboration were not disclosed.

“The expansion of our tumor bank in this selective manner will enhance our efforts of developing predictive biomarkers alongside the development of our anti-cancer stem cell therapeutics,” said Paul Hastings, President and Chief Executive Officer of OncoMed Pharmaceuticals.

“Development of characterized PDX models is a natural addition to our core competencies in working with patient-derived primary tumor cells. OncoMed is a leader in cancer stem cell therapeutics and a most discerning partner in evaluation of new PDX models. The expanded collaboration with OncoMed is proof of our success and continued commitment to enable further evaluation of cancer therapeutics in better characterized models with use of our high content cell-based platforms and exclusive patient-derived primary tumor cell bank,” said Cyrus K. Mirsaidi, Molecular Response CEO.

About Molecular Response

Molecular Response is a leader in advancing targeted therapeutics through intelligently designed, clinically validated companion diagnostics. Our goal is to reduce risk and cost of therapeutic drug development for our partners by translating clinically relevant molecular response marker data into high-value knowledge while fully integrated into existing pharmaceutical development processes and programs. Our results reduce risk and cost of drug development and allow for the most informed decisions with best chance of success to advance therapeutic programs.

For additional information please visit www.molecularresponse.com.

About OncoMed, Inc.

OncoMed Pharmaceuticals is a clinical-stage company that discovers and develops novel therapeutics targeting cancer stem cells, the cells believed to be capable of driving tumor growth, recurrence and metastasis. A leader in cancer stem cell research, the company has established a library of antibodies to cancer stem cell proteins for the treatment of solid tumors such as pancreatic, breast, colorectal and lung cancers. OncoMed has advanced three anti- cancer stem cell monoclonal antibodies into the clinic, OMP-21M18, OMP-59R5, and OMP-18R5, which target key cancer stem cell signaling pathways including Notch and Wnt. In addition, OncoMed’s pipeline includes several novel preclinical product candidates targeting multiple validated cancer stem cell pathways. OncoMed has formed strategic alliances with Bayer HealthCare Pharmaceuticals and GlaxoSmithKline. Privately-held, OncoMed’s investors include: US Venture Partners, Latterell Venture Partners, The Vertical Group, Morgenthaler Ventures, Phase4 Ventures, Delphi Ventures, Adams Street Partners, De Novo Ventures, Bay Partners and GlaxoSmithKline. Additional information can be found at the company’s website: www.oncomed.com.

The rest is here:
Molecular Response Announces Key Agreement in Translational Oncology with OncoMed Pharmaceuticals

Posted in Oncology | Tagged , , , , , , , , , , , , , | Comments Off